Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive January 21, 2014 William Looney	Russia's Bet on Biopharma Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector
Pharmaceutical Executive July 1, 2013 William Looney	Talent, Terror, and the Turnaround We offer news on 15 new Emerging Pharma Leaders, business innovation, and terrorism threats to the pharmaceutical industry.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
The Motley Fool September 7, 2011 Travis Hoium	Europe Puts Kibosh on Syrian Oil The Arab Spring is starting to have a major impact on companies' oil revenues.
Pharmaceutical Executive May 1, 2012 William Looney	Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever.
Pharmaceutical Executive December 1, 2010	The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs.
The Motley Fool December 5, 2011 Aimee Duffy	Big Oil's Trouble Abroad Foreign tumult halts production for major oil companies.
Pharmaceutical Executive March 1, 2011 William Looney	Making Sense of Market Chaos Pharma can be an insular industry, with limited capacity to gaze beyond its own narrow frame of vision
Pharmaceutical Executive May 1, 2011 William Looney	Keeping Your Place on the Nifty 50 What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.
Pharmaceutical Executive September 1, 2014 William Looney	Ireland's Celtic Tiger: Back on the Hunt Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.
Pharmaceutical Executive October 1, 2010	Nobel Laureate Elie Wiesel Exclusive Interview Ethical behavior can be a bridge-builder in an era where Big Pharma needs to find new partners. Is it up to the challenge?
BusinessWeek November 8, 2004 Stanley Reed	Can Assad Halt Syria's Diplomatic Slide? Syria's young president, Bashar Al-Assad, has been sailing along oblivious to the dangers his government has been courting. Now he's waking up fast.
Pharmaceutical Executive December 1, 2012 William Looney	The Puzzle Master: Dr. Guido Rasi Europe's chief regulator charts a strategy from many moving parts.
Pharmaceutical Executive September 1, 2010	Looking Beyond the Patent Cliff Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP.
Pharmaceutical Executive January 1, 2011	The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs
Pharmaceutical Executive January 21, 2014 William Looney	For Russia -- Tough Love Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exist.
Pharmaceutical Executive January 1, 2012 William Looney	The Well of Engagement We sometimes forget that the business of healthcare is also the source of a huge opportunity: improving the human condition.
Pharmaceutical Executive July 1, 2005 Sarah Houlton	Global Report: Still Waiting Pharma industry and traders both want a decision on parallel trade in Europe--but not the same one.
Chemistry World June 23, 2010 Sarah Houlton	A smaller future for big pharma? Cutting the amount spent on medicines may be an easy way for governments to help balance the books in the short term, but in the long run it will impact the ability to discover new medicines.
Pharmaceutical Executive April 1, 2006 Ron Feemster	Thought Leader: Q&A with Joel A. Tune Pharma still enlists contract manufacturers as safety valves, but today's drug developers have also begun to outsource the production of increasingly complicated compounds while they are still in clinical trials.
Chemistry World December 15, 2009 Sarah Houlton	Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu.
Pharmaceutical Executive October 1, 2006 Sarah Houlton	Global Report: Please Come Back Health authorities in Europe are working hard to reestablish their countries as preferred locations for pharma's R&D facilities. Fortunately, they've got a blueprint: China.
BusinessWeek May 27, 2010 Charlie Rose	Charlie Rose Talks to Bashar al-Assad Syria's President on what the U.S. doesn't understand about the Mideast and the prospects for peace.
BusinessWeek May 12, 2011 Charlie Rose	Charlie Rose Talks to Recep Tayyip Erdogan Turkey's Prime Minister on the violent stalemates in Syria and Libya, the Israel-Palestine peace process, and the roadblocks to EU membership for his nation
Pharmaceutical Executive December 1, 2011 William Looney	2011: End of the Beginning The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item.
Chemistry World July 10, 2012	Interview: EMA head Guido Rasi His five-year appointment comes during a period of dramatic change for the pharma industry, which is struggling with patent expirations for many of its biggest selling drugs and a paucity of new drugs coming through the pipeline to take their place.
Pharmaceutical Executive January 21, 2014 Comer & Upton	Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.
Pharmaceutical Executive January 1, 2006 Sarah Houlton	Global Report: The UK's New Code of Conduct Pharma companies' relationships with doctors are being tightened in the United Kingdom, after a major overhaul of the Association of the British Pharmaceutical Industry's Code of Practice.
Pharmaceutical Executive November 1, 2006 Sarah Houlton	Global Report: 'Bout Time The European Union has been late to enter the fight against counterfeiting. Fed up, Parliament has passed a proposal designed to give its countries the nudge they need.
The Motley Fool October 11, 2011 Cliff D'Arcy	AstraZeneca Loves This $100Bn Market The British pharma firm makes its largest-ever manufacturing investment -- in China.
Pharmaceutical Executive May 1, 2011	Seeing Through the Transparency Directive The EU is largely powerless when it comes to policies over pharma pricing and reimbursement.
Chemistry World January 3, 2013 Sarah Houlton	2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012.
Pharmaceutical Executive April 1, 2005	Thought Leader: Better Business: Balancing Benefit, Risk, and Cost An interview with author and Harvard Medical School professor Dr. Jerry Avorn on how losing track of patient welfare and failing to address important safety problems isn't just bad science and bad ethics, it's also bad business.
Reason November 2003 Charles Paul Freund	Arabian Idol: Reality TV tames nationalism A different sort of conflict broke out this summer in the Middle East -- one involving reality TV. While it offers more evidence that the region is in the grip of a liberationist pop culture frenzy, it also demonstrates that even the region's pop fandom can fall prey to divisiveness.
Chemistry World July 25, 2012	Drugs Top EU Counterfeit Imports In 2011, EU customs officers stopped 115 million products suspected of violating intellectual property rights. Medicines top the list, accounting for 24% of those items.
Pharmaceutical Executive May 1, 2012	Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity?
Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Smithsonian July 2005 Stephen Glain	Syria at a Crossroads Following a humbling retreat from Lebanon and increasingly at odds with the U.S., the proud Arab nation finds itself at a critical juncture.
Pharmaceutical Executive February 1, 2011 William Looney	To Align an Audience, Find a Pulse All this uncertainty at the back end of drug development is a drain on future therapeutic progress against disease. It's a job killer, too.
Chemistry World May 7, 2014 Phillip Broadwith	UK regulator warning over online herbal remedies The UK's Medicines and Healthcare products Regulatory Agency has found that several herbal medicines available over the internet are contaminated with prescription-only drugs or toxic heavy metals.
Pharmaceutical Executive April 1, 2011	How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Pharmaceutical Executive October 1, 2014 William Looney	IDEAlogue for Innovation Professor Fabio Pammolli, a leading European economist and policy advisor to the key EU institutions, outlines the current dilemma facing health and pharma regulators in Europe today.
Pharmaceutical Executive July 1, 2011 William Looney	Truth Found in the Wrong Places More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them.
Salon.com June 13, 2000 Flore de Preneuf	Is Syria's next president a geek? He loves technology. He wants to bring the Internet to Damascus. But can the Israelis learn to love him?
Pharmaceutical Executive January 1, 2012 William Looney	Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.
Pharmaceutical Executive June 9, 2014 Kleinrock & Noor	Pharm Exec's Pharma 50 2014 For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.
Salon.com February 28, 2001 Fiona Morgan	Washington sobers up on sanctions The Bush administration plans to abandon 10 years of failed Iraqi policy and instead hit Saddam where it will hurt him most: His cash-lined pockets...
Pharmaceutical Executive August 1, 2013 William Looney	One Company -- One Moment The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China -- ironically, the country touted as guarantor of our industry's future.